[Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602].
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001593:Benzyl Compounds / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002214:Capsules; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006834:Hydrazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D012694:Serine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
D000978:Antiparkinson Agents; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001593:Benzyl Compounds; D002214:Capsules; D006834:Hydrazines; D012694:Serine; D004295:Dihydroxyphenylalanine
Traitement de la maladie de Parkinson avec la L-dopa seule ou associée au Ro 4-4602, étude comparative.